Workflow
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Globenewswire· 2025-09-09 11:00
Core Insights - Regeneron Pharmaceuticals announced five-year follow-up results from the Phase 3 EMPOWER-Lung 3 trial, showing that Libtayo (cemiplimab) combined with chemotherapy significantly improves overall survival rates in patients with advanced non-small cell lung cancer (NSCLC) [1][2][4] - The trial demonstrated a five-year overall survival rate of 19.4% for the Libtayo combination compared to 8.8% for chemotherapy alone, indicating a substantial clinical benefit [1][4] - Notable efficacy was observed across different tumor histologies, particularly in squamous NSCLC patients, who had a median overall survival of 22.3 months [2][4] Summary by Sections Trial Results - The EMPOWER-Lung 3 trial involved 466 patients with locally advanced or metastatic NSCLC, comparing Libtayo plus platinum-based chemotherapy to chemotherapy alone [6][8] - The five-year analysis showed a median overall survival of 21.1 months for the Libtayo group versus 12.9 months for chemotherapy alone, representing a 34% reduction in the risk of death [4] - The median progression-free survival was 8.2 months for the Libtayo combination compared to 5.5 months for chemotherapy, indicating a 42% reduction in disease progression risk [4] Safety Profile - The safety profile of Libtayo plus chemotherapy remained consistent over five years, with adverse events occurring in 96.5% of patients receiving the combination [3][5] - Common adverse events included anemia (46%), alopecia (38%), and nausea (25%), with 49% of adverse events being grade 3 or higher [3][5] Efficacy Across Subgroups - Exploratory subgroup analyses indicated survival benefits for patients treated with Libtayo plus chemotherapy regardless of tumor histology or PD-L1 expression level [3] - The objective response rate was 43.6% for the Libtayo combination compared to 22.1% for chemotherapy alone, with a complete response rate of 6.4% versus 0% [4] Company Overview - Regeneron is focused on developing innovative therapies for serious diseases, with Libtayo being a key asset in its oncology pipeline [10][26] - The company utilizes its proprietary VelocImmune technology to create fully human monoclonal antibodies, including Libtayo, which targets the PD-1 immune checkpoint [12][25]
Scorpio Tankers Inc. Announces a Vessel Sale Agreement
Globenewswire· 2025-09-09 10:30
MONACO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced that the Company has entered into an agreement to sell its 2020 built scrubber-fitted MR product tanker, STI Maestro. The sale price is $42.0 million and the sale is expected to close within the fourth quarter of 2025. About Scorpio Tankers Inc. Scorpio Tankers Inc. is a provider of marine transportation of petroleum products worldwide. Scorpio Tankers Inc. currently owns or lease fina ...
eGain Appoints Marketing Veteran John Copeland as Vice President of Marketing
Globenewswire· 2025-09-09 10:30
Seasoned executive brings years of experience driving growth through data-driven marketing strategies at Adobe, ServiceNow, eBay, and McKinseySUNNYVALE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- eGain Corporation, a leading provider of AI CX automation powered by Trusted Knowledge™, today announced the appointment of John Copeland as Vice President of Marketing. Copeland brings extensive experience in marketing analytics, digital transformation, and go-to-market strategy from his leadership roles at some o ...
Nova Announces Strategic Investment in Adelong Gold
Globenewswire· 2025-09-09 10:30
Melbourne, Australia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to announce a strategic cornerstone investment representing 7.8% of the ordinary shares in Adelong Gold Limited (ASX: ADG) (Adelong), a gold-antimony focused exploration and near-term production company with a diversified portfolio of high-grade projects across Australia and Brazil. This investment forms part of Nova’s ongoing strategy to partner with unde ...
Delicious Fast-Acting HaHa Soft Chews, Top Sellers at Planet 13 Las Vegas, are Now Available in Florida at Planet 13 Dispensaries across the Sunshine State
Globenewswire· 2025-09-09 10:30
Made with real Fruit Juices, HaHa Soft Chews (AKA gummies) are vegan, gluten-free, and melt-resistant. This is just the beginning for Planet 13’s Florida edibles offerings, with Sugar-free HaHa and Dreamland Chocolates coming soon.LAS VEGAS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, is pleased to announce Nano HaHa Soft Chews are now available at all of its Planet 13 store ...
Form 8.5 (EPT/RI)-Treatt plc
Globenewswire· 2025-09-09 10:14
Key Information - The exempt principal trader involved is Investec Bank plc, which is acting in a client-serving capacity for Treatt plc [1] - The date of the dealings was September 8, 2025 [1] Dealings by the Exempt Principal Trader - Investec Bank plc purchased a total of 510,111 ordinary shares at prices ranging from 262 to 270 [3] - The bank sold 458,722 ordinary shares at prices ranging from 262 to 270 [3] Other Information - There are no indemnity or option arrangements related to the relevant securities [8] - There are no agreements or understandings regarding voting rights or future acquisition or disposal of relevant securities [9]
Gilat Announces Private Placement of US$66 Million to Institutional and Accredited Investors
Globenewswire· 2025-09-09 10:10
Core Viewpoint - Gilat Satellite Networks Ltd. has announced a private placement of Ordinary Shares to Israeli institutional and accredited investors, aiming to raise approximately $65 million for general corporate purposes [1][3]. Group 1: Private Placement Details - The company plans to issue 7,058,820 Ordinary Shares at a price of $9.35 per share, reflecting a 6.3% discount to the 7-day Volume Weighted Average Price [2]. - The newly issued shares will account for about 11% of the company's total issued and outstanding Ordinary Shares post-transaction [2]. - The transaction is expected to close in September 2025, subject to customary closing conditions [2]. Group 2: Financial Implications - The net proceeds from the share sale, after deducting offering expenses, are anticipated to be around $65 million [3]. - The funds will be utilized for general corporate purposes, indicating a focus on strengthening the company's operational capabilities [3]. Group 3: Regulatory and Market Context - The private placement is exclusively for investors in Israel and will not be offered to U.S. persons, adhering to Regulation S under the U.S. Securities Act [4]. - The shares will not be registered under the Securities Act and will be subject to transfer restrictions [4]. Group 4: Company Overview - Gilat Satellite Networks Ltd. is a leading provider of satellite-based broadband communications with over 35 years of experience [7]. - The company offers a range of solutions for satellite, ground, and new space connectivity, catering to both commercial and defense applications [7][8]. - Its product portfolio includes high-performance satellite terminals, advanced antennas, and integrated ground systems, supporting various applications such as government, defense, and critical infrastructure [9][10].
Ambow Education Launches HybriU® 3D Mobile Station, Redefining 3D Production and Broadcasting with Seamless Portability
Globenewswire· 2025-09-09 10:00
Core Viewpoint - Ambow Education Holding Ltd. has launched the HybriU® 3D Mobile Station, a self-contained cart designed to facilitate immersive 3D broadcasting and collaboration, making it accessible for various industries including education, corporate, and entertainment [1][3][4]. Group 1: Product Overview - The HybriU 3D Mobile Station utilizes proprietary end-to-end 3D technology to capture, encode, transform, decode, and display 3D signals in real time, integrating the entire video production workflow into a single portable unit [2][5]. - This innovative product allows for immersive 3D experiences to be delivered instantly to audiences through various platforms such as 3D LED walls, IMAX theaters, and VR headsets [3][4]. Group 2: Market Impact - The launch of the HybriU 3D Mobile Station aims to democratize immersive 3D broadcasting, enabling educators, enterprises, and event organizers to create lifelike experiences without the need for specialized infrastructure [4][5]. - The product is designed to serve a wide range of industries, facilitating hybrid classrooms, live event broadcasting, and immersive corporate training sessions [4][5]. Group 3: Strategic Positioning - The introduction of the HybriU 3D Mobile Station strengthens Ambow's portfolio and reflects the company's strategy to expand beyond the education sector into corporate and entertainment markets [5][6]. - By bridging physical and digital experiences, Ambow positions itself at the forefront of immersive communication and collaboration technologies [5][6].
Sono Group N.V. Announces CEO Transition; Supervisory Board Nominates Kevin McGurn as Chief Executive Officer
Globenewswire· 2025-09-09 10:00
After steering Sono from automotive roots to solar tech and the uplisting to the Nasdaq Capital Market, George O’Leary passes the baton; Kevin McGurn nominated to accelerate commercialization and partnershipsMunich, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sono Group N.V. (Nasdaq: SSM) (hereafter referred to as “Sono” or the “Company”, parent company to Sono Motors GmbH, hereafter referred to as “SonoSolar” or “Subsidiary”), the solar technology company after its uplisting to Nasdaq, today announced that George G ...
Constellium Extends Partnership with Embraer for Advanced Aluminum Aerospace Solutions
Globenewswire· 2025-09-09 10:00
PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) is pleased to announce the extension of its long-term partnership with Embraer for the supply of high-performance aluminum solutions, including its advanced aluminum-lithium alloy, Airware®. Under this agreement, Constellium will continue to support Embraer’s Commercial Aviation, Executive Jets, and Defense & Security divisions. “We are proud and honored to extend our long-term partnership with Embraer in the aerospace and defense sectors ...